Public Sector Pension Investment Board grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 18.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,852 shares of the pharmaceutical company’s stock after buying an additional 7,518 shares during the quarter. Public Sector Pension Investment Board’s holdings in Vertex Pharmaceuticals were worth $23,815,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Vertex Pharmaceuticals in the second quarter valued at approximately $11,975,849,000. State Street Corp boosted its stake in Vertex Pharmaceuticals by 1.2% in the second quarter. State Street Corp now owns 11,871,459 shares of the pharmaceutical company’s stock valued at $5,896,910,000 after acquiring an additional 141,320 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Vertex Pharmaceuticals by 1.1% in the 2nd quarter. Wellington Management Group LLP now owns 3,247,658 shares of the pharmaceutical company’s stock valued at $1,613,209,000 after purchasing an additional 35,069 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Vertex Pharmaceuticals by 1.0% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,086,683 shares of the pharmaceutical company’s stock worth $1,533,248,000 after acquiring an additional 29,287 shares during the last quarter. Finally, Bank of America Corp DE acquired a new position in Vertex Pharmaceuticals in the second quarter valued at $1,509,651,000. 90.96% of the stock is owned by hedge funds and other institutional investors.
Vertex Pharmaceuticals Trading Down 2.9%
Shares of VRTX opened at $520.66 on Friday. The stock’s 50-day moving average is $522.74 and its two-hundred day moving average is $485.01. The stock has a market cap of $132.01 billion, a PE ratio of 33.50, a P/E/G ratio of 2.84 and a beta of 0.28. Vertex Pharmaceuticals Incorporated has a 12 month low of $412.27 and a 12 month high of $568.67. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.34 and a quick ratio of 1.89.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last issued its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.06). The company had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. Vertex Pharmaceuticals’s quarterly revenue was up 11.8% on a year-over-year basis. During the same period in the previous year, the company earned $4.80 EPS. Equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.10 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, Director Nancy Thornberry sold 1,000 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $547.86, for a total transaction of $547,860.00. Following the sale, the director owned 1,109 shares in the company, valued at $607,576.74. This trade represents a 47.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sangeeta Bhatia sold 271 shares of the business’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $547.86, for a total transaction of $148,470.06. Following the transaction, the director directly owned 4,653 shares in the company, valued at approximately $2,549,192.58. The trade was a 5.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 16,557 shares of company stock valued at $9,071,071. Corporate insiders own 0.20% of the company’s stock.
Top Vertex Pharmaceuticals Stories
Investors following VRTX have been watching these stories:
- Positive Sentiment: Vertex and Genomics extended their drug-target discovery collaboration by four years. The alliance, reportedly valued at $220 million, uses human genetics to identify and validate targets for potential precision medicines, supporting Vertex’s longer-term research pipeline. Article: Genomics and Vertex extend alliance
- Neutral Sentiment: Vertex is studying the at-home injector experience in an IgA nephropathy trial. The update concerns administration and patient experience; the supplied report does not cite new efficacy or safety results. Article: At-home injector study
- Neutral Sentiment: Investors are watching for the expected November 30 U.S. regulatory decision on povetacicept and further late-stage pipeline updates, potential catalysts whose outcomes remain uncertain. Article: Pipeline and regulatory outlook
Analyst Ratings Changes
Several research firms have recently commented on VRTX. Wells Fargo & Company increased their price target on Vertex Pharmaceuticals from $550.00 to $650.00 and gave the stock an “overweight” rating in a report on Tuesday, November 3rd. Canaccord Genuity Group upped their price target on Vertex Pharmaceuticals from $436.00 to $442.00 and gave the stock a “hold” rating in a report on Tuesday, August 4th. Evercore lifted their target price on shares of Vertex Pharmaceuticals from $535.00 to $600.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 2nd. Leerink Partners began coverage on Vertex Pharmaceuticals in a report on Monday, September 21st. They issued an “outperform” rating and a $594.00 price target for the company. Finally, Jefferies Financial Group raised their target price on shares of Vertex Pharmaceuticals from $633.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $596.44.
Get Our Latest Research Report on VRTX
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
Recommended Stories
- Five stocks we like better than Vertex Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
